Considerations for treatment duration in responders to immune checkpoint inhibitors

Thomas U. Marron, Aideen E. Ryan, Sangeetha M. Reddy, Sabina Kaczanowska, Rania H. Younis, Dipti Thakkar, Jiajia Zhang, Todd Bartkowiak, Rachel Howard, Kristin G. Anderson, Daniel Olson, Abdul Rafeh Naqash, Ravi B. Patel, Esha Sachdev, Maria E. Rodriguez-Ruiz, Michal Sheffer, Sarah Church, Christopher Fuhrman, Abigail Overacre-Delgoffe, Rosa NguyenVaia Florou, Jessica E. Thaxton, David H. Aggen, Jennifer L. Guerriero

Research output: Contribution to journalReview articlepeer-review

69 Scopus citations


Immune checkpoint inhibitors (ICIs) have improved overall survival for cancer patients, however, optimal duration of ICI therapy has yet to be defined. Given ICIs were first used to treat patients with metastatic melanoma, a condition that at the time was incurable, little attention was initially paid to how much therapy would be needed for a durable response. As the early immunotherapy trials have matured past 10 years, a significant per cent of patients have demonstrated durable responses; it is now time to determine whether patients have been overtreated, and if durable remissions can still be achieved with less therapy, limiting the physical and financial toxicity associated with years of treatment. Well-designed trials are needed to identify optimal duration of therapy, and to define biomarkers to predict who would benefit from shorter courses of immunotherapy. Here, we outline key questions related to health, financial and societal toxicities of over treating with ICI and present four unique clinical trials aimed at exposing criteria for early cessation of ICI. Taken together, there is a serious liability to overtreating patients with ICI and future work is warranted to determine when it is safe to stop ICI.

Original languageEnglish
Article numbere001901
JournalJournal for ImmunoTherapy of Cancer
Issue number3
StatePublished - 2 Mar 2021


  • Costimulatory and Inhibitory T-Cell Receptors
  • Immunotherapy
  • Melanoma
  • Review


Dive into the research topics of 'Considerations for treatment duration in responders to immune checkpoint inhibitors'. Together they form a unique fingerprint.

Cite this